Antibodies to paliperidone and use thereof
Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone/paliperidone in a single lateral flow assay device.
1. An isolated antibody or a binding fragment thereof, which specifically binds to paliperidone and which said isolated antibody or binding fragment thereof is selected from the group of amino acid sequences consisting of:
a) the isolated antibody or the binding fragment thereof comprising a heavy chain variable region, and a light chain variable region wherein said light chain variable region comprising an amino acid sequence of SEQ ID NO:3 or SEQ ID NO:7;
b) the isolated antibody or the binding fragment thereof comprising a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:4 or SEQ ID NO:8, and a light chain variable region;
c) the isolated antibody or the binding fragment thereof comprising a light chain variable region having an amino acid sequence of SEQ ID NO:3 and a heavy chain variable region having an amino acid sequence of SEQ ID NO:4; or
d) the isolated antibody or the binding fragment thereof comprising a light chain variable region having an amino acid sequence of SEQ ID NO:7 and a heavy chain variable region having an amino acid sequence of SEQ ID NO:8.
2. The isolated antibody of claim 1 , wherein the antibody comprises the light chain variable region having the amino acid sequence SEQ ID NO:3 and the heavy chain variable region having the amino acid sequence SEQ ID NO:4.
3. The isolated antibody of claim 1 , wherein the antibody comprises the light chain variable region having the amino acid sequence SEQ ID NO:7 and the heavy chain variable region having the amino acid sequence SEQ ID NO:8.
4. The isolated antibody of claim 1 , wherein the antibody comprises:
a) a light chain CDR1 sequence comprising amino acid residues 44 to 60 of SEQ ID NO:3;
b) a light chain CDR2 sequence comprising amino acid residues 76 to 82 of SEQ ID NO:3;
c) a light chain CDR3 sequence comprising amino acid residues 115 to 123 of SEQ ID NO:3;
d) a heavy chain CDR1 sequence comprising amino acid residues 45 to 54 of SEQ ID NO:4;
e) a heavy chain CDR2 sequence comprising amino acid residues 69 to 85 of SEQ ID NO:4; and
f) a heavy chain CDR3 sequence comprising amino acid residues 118 to 122 of SEQ ID NO:4.
5. The isolated antibody of claim 1 , wherein the antibody comprises:
a) a light chain CDR1 sequence comprising amino acid residues 44 to 60 of SEQ ID NO:7;
b) a light chain CDR2 sequence comprising amino acid residues 76 to 82 of SEQ ID NO:7;
c) a light chain CDR3 sequence comprising amino acid residues 115 to 123 of SEQ ID NO:7;
d) a heavy chain CDR1 sequence comprising amino acid residues 45 to 54 of SEQ ID NO:8;
e) a heavy chain CDR2 sequence comprising amino acid residues 69 to 85 of SEQ ID NO:8; and
f) a heavy chain CDR3 sequence comprising amino acid residues 118 to 122 of SEQ ID NO:8.
6. The isolated antibody of claim 1 , wherein the antibody fragment is selected from the group of fragments consisting of Fv, F(ab'), F(ab')2, scFv, minibody and diabody fragments.
7. The isolated antibody of claim 1 , wherein the antibody is a monoclonal antibody.
8. An assay kit comprising the isolated antibody of claim 1 .
9. An assay device comprising the isolated antibody of claim 1 .
10. The assay device of claim 9 wherein the device is a lateral flow assay device.
11. A method of detecting paliperidone in a sample, the method comprising:
(i) contacting a sample with the isolated antibody of claim 1 labeled with a detectable marker, wherein the labeled antibody and paliperidone present in the sample form a labeled complex; and
(ii) detecting the labeled complex so as to detect paliperidone in the sample.
12. A competitive immunoassay method for detecting paliperidone in a sample, the method comprising:
(i) contacting a sample with the isolated antibody of claim 1 , and with paliperidone or a competitive binding partner thereof, wherein one of the isolated antibody and the paliperidone or competitive binding partner thereof is labeled with a detectable marker, and wherein sample paliperidone competes with the paliperidone or competitive binding partner thereof for binding to the isolated antibody; and
(ii) detecting the label so as to detect sample paliperidone.
13. The method of claim 12 wherein the paliperidone or competitive binding partner thereof is labeled with the detectable marker.
14. The method of claim 12 wherein the antibody is labeled with a detectable marker.
15. The method of claim 12 wherein the immunoassay is performed on a lateral flow assay device and the sample is applied to the device.
16. The method of claim 11 or 12 , further comprising detecting the presence of one or more analytes in addition to paliperidone.
17. The method of claim 16 wherein the one or more analytes are anti-psychotic drugs other than paliperidone.
18. The method of claim 17 wherein the anti-psychotic drugs other than paliperidone are selected from the group consisting of: risperidone, quetiapine, olanzapine, aripiprazole, and metabolites thereof.